What dermatologic diseases are associated with the HLA‑DQB1*0301 allele?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

HLA-DQB1*0301 Associated Dermatologic Illnesses

The HLA-DQB1*0301 allele is most strongly and consistently associated with bullous pemphigoid (BP) and its clinical variants, including ocular cicatricial pemphigoid (OCP) and oral pemphigoid (OP).

Primary Dermatologic Association: Bullous Pemphigoid

The evidence overwhelmingly demonstrates that HLA-DQB1*0301 is a major genetic susceptibility marker for bullous pemphigoid, the most common autoimmune subepidermal blistering disease 1, 2. This association has been validated across multiple populations and clinical presentations:

Bullous Pemphigoid (BP)

  • DQB1*0301 is present in approximately 54-76% of BP patients compared to 21-33% in matched controls 2, 3, 4
  • The relative risk ranges from 4.23 to 6.4 for developing BP when carrying this allele 3, 4
  • This association is particularly strong when DQB10301 forms haplotypes with *DRB11101* (24% in BP vs 6.6% in controls) 3

Clinical Variants with DQB1*0301 Association

Ocular Cicatricial Pemphigoid (OCP):

  • Shows the strongest association, with 76% of patients carrying DQB1*0301 (p < 0.005) 4
  • Relative risk of 8.0 for pure ocular disease 4
  • The significantly increased frequency in ocular disease suggests this allele predisposes specifically to scarring processes affecting the conjunctiva 4

Oral Pemphigoid (OP):

  • 68% of patients with oral mucosal involvement carry DQB1*0301 (p < 0.025) 4
  • When ocular disease is excluded, the association becomes less significant, suggesting the allele's primary effect may be on ocular manifestations 4

Mucous Membrane Pemphigoid (MMP):

  • Meta-analysis shows OR of 5.25 (95% CI: 4.03-6.84) for MMP, significantly higher than the OR of 2.22 for BP (p = 0.007) 1

Drug-Induced Bullous Pemphigoid

Gliptin-associated BP (GABP) shows an even stronger association with DQB1*0301:

  • The risk conferred by DQB1*0301 is significantly higher in dipeptidyl peptidase-4 inhibitor-induced BP compared to idiopathic BP 1
  • In Italian patients, both idiopathic and gliptin-associated BP showed significant association with DQB10301, particularly with the haplotypes *DRB111:01-DRB3*02:02-DQA105:05-DQB103:01* or DRB111:04-DRB302:02-DQA105:05-DQB103:01 5

Pathogenic Mechanism

The multi-hit hypothesis explains how DQB1*0301 contributes to BP pathogenesis 6:

  1. Antigen exposure: Patients with underlying neuronal disease (BP is associated with neurocognitive disorders) are exposed to previously sequestered BP180 antigen
  2. HLA-mediated presentation: DQB1*0301 binds to the immunogenic BP180-NC16a domain with increased T-cell avidity
  3. Loss of tolerance: In patients with dysregulated Th1/Th2 balance, anergy is lost and T-cells become primed
  4. Autoimmunity development: Functional autoimmunity against BP180-NC16a develops, leading to clinically overt disease

The critical amino acid sequence from positions 71-77 (Thr-Arg-Ala-Glu-Leu-Val-Thr) shared by DQB1*0301, *0302, *0303, and *06 alleles appears important for peptide binding and disease susceptibility 2.

Clinical Implications

Risk Stratification

  • Patients with DQB1*0301 who require gliptin therapy should be counseled about increased BP risk
  • The presence of DQB10301 with DRB11101 confers the highest risk profile
  • Ocular involvement is more likely in DQB1*0301-positive patients and requires vigilant monitoring

Protective Alleles

Conversely, DQA1*0201 appears protective against pemphigoid (OR = 0.3,95% CI: 0.17-0.52) with no heterogeneity across studies 1. The DRB10701-DQB10202 haplotype also shows negative association 3.

Important Caveats

  • While HLA-DQB1*0301 is strongly associated with BP, it is neither necessary nor sufficient for disease development—many carriers never develop BP, and some BP patients lack this allele
  • The association is specific to pemphigoid variants and does not extend to other subepidermal blistering diseases like epidermolysis bullosa acquisita
  • HLA typing is not routinely recommended for clinical diagnosis or management of BP, as diagnosis relies on clinical presentation, histopathology, and direct immunofluorescence 7

References

2
Research

A common major histocompatibility complex class II allele HLA-DQB1* 0301 is present in clinical variants of pemphigoid.

Proceedings of the National Academy of Sciences of the United States of America, 1996

Related Questions

What illnesses are associated with the HLA‑DQB1*0301 allele?
What genetic factors are associated with mucous membrane pemphigoid?
What should I do now that the iodoform‑saline pack placed after incision and drainage of a right labial abscess fell out four days post‑procedure?
Can Meniere's disease present without hearing loss, manifesting only as vertigo episodes?
How can I determine if a patient has thyromegaly on physical examination, and what size defines an enlarged thyroid?
What is the success rate of mandibular advancement device (MAD) or oral appliance therapy (OAT) for adults with moderate obstructive sleep apnea?
Can I prescribe tiotropium (Spiriva) for her?
What is the diagnosis and treatment for the patient’s condition?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.